首页> 外文期刊>Expert opinion on therapeutic targets >Triple-negative breast cancer: investigating potential molecular therapeutic target
【24h】

Triple-negative breast cancer: investigating potential molecular therapeutic target

机译:三阴性乳腺癌:研究潜在的分子治疗靶标

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Triple-negative breast cancer (TNBC) makes up about 10 - 20% of all breast cancers and the lack of hormone receptors and human epidermal growth factor receptor-2/Neu expression is responsible for poor prognosis, no targeted therapies and trouble in the clinical management. Tumor heterogeneity, also within the same tumor, is a major cause for this difficulty. Based on the introduction of new biological drugs against different kinds of tumor, many efforts have been made for classification of genetic alterations present in TNBC, leading to the identification of several oncogenes and tumor suppressor genes involved in breast cancer carcinogenesis.
机译:简介:三阴性乳腺癌(TNBC)约占所有乳腺癌的10-20%,并且缺乏激素受体和人类表皮生长因子受体2 / Neu的表达导致预后不良,无针对性的治疗和治疗中的麻烦临床管理。同样在同一肿瘤内的肿瘤异质性是造成该困难的主要原因。基于针对不同类型肿瘤的新生物药物的引入,已经做出了许多努力来对TNBC中存在的遗传变异进行分类,从而鉴定出了与乳腺癌致癌相关的几种癌基因和抑癌基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号